TABLE 4.
Antiviral activities of compounds 22 and trans-14 against several ZIKV laboratory and clinical strains evaluated in four susceptible cell lines
| Compound | EC50 (μM)a |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vero |
Huh |
Jeg3 |
A549 |
|||||||||
| MR766 | PR | FLR | MR766 | PR | FLR | MR766 | PR | FLR | MR766 | PR | FLR | |
| 22 | >100 | >100 | >100 | >100 | >100 | >100 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.6 | 0.1 ± 0.05 | 0.2 ± 0.1 | 0.1 ± 0.04 |
| trans-14 | >100 | >100 | >100 | >100 | >100 | >100 | 0.2 ± 0.05 | 0.7 ± 0.3 | 1.2 ± 1.0 | 0.2 ± 0.1 | 0.6 ± 0.4 | 0.2 ± 0.1 |
a
Data are averages ± SD from at least three independent experiments. EC50s against ZIKV MR766 in Vero cells are from Table 1.